Outset Medical

Outset Medical, Inc. is a medical technology company, which provides dialysis solutions to patients and healthcare providers. Its product Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Outset Medical reports robust Q4 performance and eyes home market growth

Outset Medical's Q4 performance showcased strong growth in Tablo Consoles and revenue, with a focus on expanding home dialysis programs and improving patient experience.
The company's strategic initiatives to manage expenses, reduce inventory levels, and enhance cash flow position it for sustainable growth and operational efficiency.
Challenges lie in meeting revenue guidance, sustaining margin expansion, and optimizing sales force efficiency, while opportunities exist in expanding home programs and leveraging partnerships for growth.
Overall, Outset Medical's performance reflects a balanced approach to growth, operational excellence, and strategic positioning in the dialysis market.

Outset Medical excels in Q1 2023, eyes home dialysis growth

Outset Medical's Q1 2023 performance was robust, with revenue growth and margin expansion surpassing expectations.
The company's focus on innovation, margin improvement, and market expansion positions it well for sustained growth.
Challenges in managing expenses and cash burn require attention, but opportunities in home dialysis and premium offerings offer avenues for future growth.

Outset Medical reports strong Q2 results, eyes sustained growth

Outset Medical delivered robust Q2 2023 results, focusing on revenue growth, margin improvement, and commercial progress in acute and home markets. The company reiterated its revenue guidance for 2023 and expressed confidence in Q4 growth driven by business visibility and network effects.
Despite facing challenges related to FDA compliance and market expansion, Outset Medical showcased strengths in customer base expansion, service margin improvement, and market acceptance of Tablo. The company's commitment to patient and provider autonomy underpins its dedication to delivering quality healthcare solutions.
With opportunities to present economic analysis data, drive utilization in acute care settings, and capitalize on Tablo's value proposition, Outset Medical is poised for sustained growth in 2024. Leveraging market trends and addressing challenges will be key to the company's success in the evolving healthcare landscape.

Outset Medical reports Q3 growth, eyes strategic expansion opportunities

Outset Medical's Q3 performance reflects steady revenue growth and margin expansion, with a focus on strategic growth initiatives.
The company's strengths lie in Tablo's success in both acute and home markets, positioning it for future growth and market expansion.
Challenges include navigating competitive pressures and achieving profitability amidst evolving market dynamics, while opportunities exist in market penetration and strategic growth avenues.

Outset Medical reports strong Q4 earnings, eyes growth opportunities

Outset Medical's Q4 performance was strong, with revenue meeting expectations and showing growth, driven by recurring revenue and expense reductions.
The company's strengths lie in wide market presence, valuable software offerings, unique technology, and effective competitive response strategies.
Challenges include deepening patient census, competitive pressures, transitioning to home dialysis, and maintaining cost efficiency and quality of care.
Opportunities for Outset Medical include revenue growth through software, the shift towards home dialysis, Medicare Advantage support, and payer discussions.

Outset Medical reports Q1 revenue miss, focuses on profitability goals

Outset Medical's Q1 performance showed progress despite revenue challenges, with a focus on cost reduction and profitability.
Strengths lie in successful partnerships, nationwide coverage, and gross margin improvement.
Challenges include revenue impact from delays and the need to balance restructuring with customer experience.
Opportunities include revenue growth in Q2, pipeline expansion, and leveraging technology advantage for innovation.

Outset Medical faces sales transformation challenges amidst revenue softness

Outset Medical's Q2 2024 earnings call highlighted revenue softness from console sales but strength in treatment sales and gross margin performance. The company is undergoing a sales transformation to target mainstream enterprise adopters and expects revenue of approximately $110 million for the year.

Outset Medical reports robust Q3 results and eyes growth opportunities

Outset Medical's Q3 performance showcased revenue growth, margin expansion, and strategic focus on profitability.
While facing challenges in maintaining margins, the company remains optimistic about growth opportunities in various market segments.
Executives highlighted the importance of a conservative outlook and emphasized the strength of their order pipeline and sales transformation progress.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. Its product, Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

Outset Medical, Inc. (OM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging -62.36% in 4 Weeks, Here's Why the Trend Might Reverse for Outset Medical, Inc. (OM)

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company reducing the cost and complexity of dialysis with its Tablo® Hemodialysis System, today announced significant data findings on how the use of Tablo increases racial diversity among users, enhances patient outcomes in the Medicare fee-for-service population, and notably decreases hospital transfers in rural Alaskan communities. The five abstracts will be showcased at the American Society.

New Data Insights Unveiled at ASN Kidney Week 2023 Point to the Impact of the Tablo® Hemodialysis System on Equitable Kidney Care

Outset Medical, Inc. (OM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the third quarter of 2023 after the close of trading on Tuesday, November 7, 2023. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, wi.

Outset Medical to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023

The heavy selling pressure might have exhausted for Outset Medical, Inc. (OM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -68.16% in 4 Weeks, Here's Why You Should You Buy the Dip in Outset Medical, Inc. (OM)

Outset Medical Inc stock was downgraded by BofA Securities analysts to ‘Underperform' from ‘Buy', and its price objective was cut to $3 per share from $32, after the medical technology company reported lower-than-expected preliminary third-quarter 2023 revenue and warned of reduced capital spending in 4Q.  "We think the Underperform rating is appropriate as Outset has had multiple execution missteps now and companies without profitability have even less margin of error given there is no real profitability valuation floor," the analysts wrote.

Outset Medical analysts slash price objective after multiple missteps

Credit Suisse

BOSTON--(BUSINESS WIRE)---- $CS #classaction--Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Outset Medical Inc. ("Outset" or the "Company") (NASDAQ: OM), a medical technology company based in San Jose, California. About the Investigation On July 10, 2023, Bloomberg reported that Outset “shares decline[d] as much as 16% after receiving a warning letter from the US FDA raising two additional observations about its dialysis device, Tablo Hemodialysi.

Berman Tabacco Announces Investigation of Outset Medical Inc. (OM) for Potential Securities Law Violations

Outset Medical Inc shares sank as much as 40% in pre-market trading on Friday after the medical technology company reported lower-than-expected preliminary third-quarter 2023 revenue of $30.4 million and warned of reduced capital spending in 4Q.   Outset also said it now expects revenue for 2023 to be about $130 million, down from the company's previous forecast of $144 million to $150 million in August.

Outset Medical stock plunges on revenue hit from FDA warning letter

Outset Medical, Inc. (NASDAQ:OM ) Q3 2023 Earnings Conference Call October 12, 2023 4:30 PM ET Company Participants Jim Mazzola - VP, IR Leslie Trigg - Chair & CEO Nabeel Ahmed - CFO Conference Call Participants Suraj Kalia - Oppenheimer & Company Shagun Singh - RBC Capital Markets Operator Thank you for standing by and welcome to Outset Medical's Preliminary Third Quarter Results Conference Call. At this time, all participants are in listen-only mode.

Outset Medical, Inc. (OM) Q3 2023 Earnings Conference Call Transcript

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), today announced preliminary financial results for the third quarter ended Sept. 30, 2023, and provided updated financial guidance for 2023. Preliminary revenue for the third quarter was $30.4 million, a 9% increase over revenue of $27.8 million in the third quarter of 2022. Outset now expects revenue for 2023 to be approximately $130 million. Preliminary gross margin for the third quarter was 23.6%.

Outset Medical Reports Preliminary Third Quarter 2023 Financial Results

DaVita

Fresenius Medical Care

Novo Nordisk shares rallied after it announced it will stop its FLOW trial nearly a year earlier than expected after positive feedback on interim data for semaglutide's ability to treat kidney disease. The news sent dialysis products and services providers plunging.

Why Dialysis Stocks Plunged Today

Outset Medical, Inc. is commercializing a new hemodialysis machine for acute care and home settings. The company has reduced guidance due to pulling its TabloCart from the market to obtain 510(k) marketing clearance. Outset Medical's financial trends show rising revenue, worsening operating income, and high cash burn.

Outset Medical Faces Regulatory Delays Amid Heavy Cash Burn (Rating Downgrade)

WHITMORE LAKE, Mich.--(BUSINESS WIRE)--Trace Medical, the national leader in advanced respiratory rentals and biomedical services, has announced a long-term distribution agreement with Outset Medical to rent the Tablo® Hemodialysis System to Home Medical Equipment (HME) providers. As part of this agreement, Trace Medical will leverage its national distribution network to offer HME providers exclusive access to rent Tablo and meet the growing demand of dialysis patients seeking treatment at home.

Trace Medical & Outset Medical sign long-term distribution agreement for Tablo® Hemodialysis System

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023 at 11:55am PT / 2:55pm ET. A live and archived webcast of the fireside chat will be available on the “Investors” section of the.

Outset Medical to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ:OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Outset Medical, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK , Aug. 17, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Outset Medical, Inc. (NASDAQ: OM) resulting from allegations that Outset Medical may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Outset Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Outset Medical, Inc. Investors to Inquire About Securities Class Action Investigation - OM

LOS ANGELES, CA / ACCESSWIRE / August 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ: OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Outset Medical, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ:OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Outset Medical, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK , Aug. 3, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Outset Medical, Inc. (NASDAQ: OM) resulting from allegations that Outset Medical may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Outset Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

OM LOSS ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Outset Medical, Inc. Investors to Inquire About Securities Class Action Investigation - OM

LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ:OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Outset Medical, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Outset Medical, Inc. (NASDAQ:OM ) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET Company Participants Jim Mazzola - Vice President, Investor Relations Leslie Trigg - Chair & Chief Executive Officer Nabeel Ahmed - Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Securities Rick Wise - Stifel Shagun Singh - RBC Capital Markets Suraj Kalia - Oppenheimer & Company Josh Jennings - TD Cowen Drew Ranieri - Morgan Stanley Operator Good day, and thank you for standing-by. Welcome to Outset Medical Q2 2023 Earnings Conference Call.

Outset Medical, Inc. (OM) Q2 2023 Earnings Call Transcript

Outset Medical, Inc. (OM) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.77 per share a year ago.

Outset Medical, Inc. (OM) Reports Q2 Loss, Tops Revenue Estimates

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights Recorded net revenue of $36.0 million in the second quarter, a 44% increase compared to $25.1 million in the second quarter of 2022, and an 8% increase compared to $33.5 million in the fir.

Outset Medical Reports Second Quarter 2023 Financial Results

LOS ANGELES, CA / ACCESSWIRE / August 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ:OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Outset Medical, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ:OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Outset Medical, Inc. and Encourages Investors with Losses to Contact the Firm

News for Outset Medical Stock (OM)